Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.

thehindu.com · 2026-10-07

Granules India files Paragraph IV for Ruxolitinib ER tablets, pursuing first-to-file status and 180 days of U.S. generic exclusivity.

TickrTrends take: Granules' pursuit of first-to-file status on a generic version of Ruxolitinib could represent a significant revenue opportunity if approved, given that exclusivity periods typically provide market advantages for early entrants in the generic space. TickrTrends currently rates INCY as undervalued within the Healthcare sector, suggesting the market may not be fully pricing in competitive pressures from generic alternatives to its Ruxolitinib franchise. Investors focused on valuation should monitor the approval timeline and commercial performance of this generic entry, as it could impact INCY's future cash flows from this drug line.

Read the full story at thehindu.com →